J. Best

发表

Zebrafish: An in vivo model for the study of neurological diseases

W. Alderton, J. Best, 2008, Neuropsychiatric disease and treatment.

Epigenetic opportunities and challenges in cancer.

Nessa Carey, N. Carey, J. Best, 2010, Drug discovery today.

Epigenetic therapies for non-oncology indications.

Nessa Carey, N. Carey, J. Best, 2010, Drug discovery today.

In Vivo Characterization of Aβ(40) Changes in Brain and Cerebrospinal Fluid Using the Novel γ-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat

J. Atack, Michael A. Reilly, J. Best, 2006, Journal of Pharmacology and Experimental Therapeutics.

4-Substituted cyclohexyl sulfones as potent, orally active γ-secretase inhibitors

Euan R. Kay, R. Mortishire-Smith, Michael A. Reilly, 2006 .

The novel γ secretase inhibitor MRK-560 reduces amyloid plaque deposition without evidence of Notch-related pathology in the Tg 2576 mouse

T. Rosahl, Michael A. Reilly, J. Best, 2006 .

Non-Associative Learning in Larval Zebrafish

A. Roach, A. Fleming, J. Best, 2008, Neuropsychopharmacology.

A novel series of potent γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core

J. Best, J. G. Neduvelil, J. Castro, 2005 .

A comparative assessment of γ-secretase activity in transgenic and non-transgenic rodent brain

J. Atack, J. Best, Mark S. Shearman, 2006, Journal of Neuroscience Methods.

A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain.

J. Atack, J. Best, Julian L Goggi, 2006, Journal of neuroscience methods.

The Epigenetics of Normal Pregnancy

N. Carey, J. Best, 2013, Obstetric medicine.

Novel orally bioavailable gamma-secretase inhibitors with excellent in vivo activity.

C. Welch, I. Collins, Michael A. Reilly, 2009, Journal of medicinal chemistry.

Cyclic sulfamide gamma-secretase inhibitors.

C. Welch, J. Best, D. Beher, 2005, Bioorganic & medicinal chemistry letters.

The Novel γ Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse

Timothy Harrison, J. Atack, T. Rosahl, 2007, Journal of Pharmacology and Experimental Therapeutics.

Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]

A. Nadin, J. Atack, Michael A. Reilly, 2005, Journal of Pharmacology and Experimental Therapeutics.

A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core.

J. Best, J. G. Neduvelil, J. Castro, 2005, Bioorganic & medicinal chemistry letters.

3,4-Fused cyclohexyl sulfones as γ-secretase inhibitors

Timothy Harrison, James Peachey, A. Nadin, 2006 .

4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.

R. Mortishire-Smith, Michael A. Reilly, E. Kay, 2006, Bioorganic & medicinal chemistry letters.

Epigenetic therapies for non-oncology indications.

N. Carey, J. Best, 2010, Drug discovery today.

Epigenetic opportunities and challenges in cancer.

N. Carey, J. Best, 2010, Drug discovery today.